Home » Catalent News » Catalent to Discuss Handling & Destruction of Returned Clinical Trial Materials

Strategies for the Handling and Destruction of Returned Clinical Trial Materials to be Discussed by Catalent at GCSG Europe

Discussed by Catalent at GCSG Europe

SOMERSET, N.J. – October 15, 2019 — Catalent, a global leader in clinical supply services, today announced that Mark Woolf, its Director of Depot Networks, will present at the upcoming 6th Annual Global Clinical Supplies Group (GCSG) European Knowledge Forum, to be held at the Miragem Hotel, Cascais, Portugal, on Oct. 22 – 24, 2019.

On Wednesday, Oct. 23 and Thursday, Oct. 24 at 11:30 a.m., Mr. Woolf will present “Strategies for Returns, Reconciliation and Destruction” alongside Gal Alterovich, Managing Director, SMO Group. Mr. Woolf and Mr. Alterovich will discuss the elements of investigational medicinal product (IMP) reconciliation and destruction and explain how to overcome the challenge of site accountability. They will also discuss the advantages and disadvantages of local versus centralized destruction.

Mr. Woolf has an extensive background in global distribution, including experience at Zuellig Pharma Asia Pacific Ltd. as Regional Quality Assurance Senior Manager, and at Almac in both the U.K. and the U.S. within logistics and operations. His expertise also extends to pharmaceutical-related cold chain storage and distribution, where he has been involved in various operational logistics and business functions around the world.

To arrange a meeting with Mr. Woolf at the event, contact Richard Kerns at NEPR – richard@nepr.agency

Notes for Editors

ABOUT CATALENT

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs nearly 13,000 people, including approximately 2,400 scientists, at more than 35 facilities across five continents, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com

 

More products. Better treatments. Reliably supplied.™